This study aims to investigate the survival of COVID-19 patients who have also been diagnosed with aspergillosis, a fungal infection caused by the genus Aspergillus that often affects those with weakened immune systems, which can lead to severe respiratory illness. Patients with COVID-19 infection are at an increased risk of developing aspergillosis due to compromised immune systems. We used de-identified data from medical records of COVID-19 patients admitted to a University of California hospital between January 2020 and April 2023 and applied survival analysis techniques to determine the median survival time for patients with and without aspergillosis diagnosis. We also compared two groups, one group included patients admitted to the ICU and covid-19, positive and other group included the patient with Covid 19 associated Aspergillosis (CAPA). A patient who developed CAPA as Cohort 1, and a Patient diagnosed with Covid-19, but no CAPA developed during the study period as Cohort 2. We used the Kaplan-Meier (KM) method, Cox regression model, and Charlson Comorbidity Index (CCI) to do the survival analysis. We created KM survival curves for various patient subgroups based on age, gender, comorbidities, Antifungal use, Steroid use, BMI, and Patient on ventilation. We identified 4151 Covid-19 patients admitted to ICU, out of which 162 (3.9%) were diagnosed with CAPA (Cohort 1), and 3989 patients did not develop CAPA (Cohort 2). Out of 162 in Cohort 1, 67(41.4%) patients died, and 753(18.9%) patients Died in cohort 2. Mortality is significantly high for patients with aspergillosis infection. This study's findings will help identify the risk factors associated with aspergillosis in COVID-19 patients and inform the development of strategies for managing and treating aspergillosis in these patients. Furthermore, our study will provide insights into the effectiveness of different antifungal treatments for COVID-19 patients with CAPA.